Eupraxia Pharmaceuticals (EPRX) Income towards Parent Company (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Income towards Parent Company data on file, last reported at -$12.7 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 87.11% year-over-year to -$12.7 million in Q1 2026; TTM through Mar 2026 was -$27.8 million, a 314.34% decrease from a year earlier, with the FY2025 full-year figure at -$38.6 million, down 49.96% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$12.7 million, down from -$6.4 million in the prior quarter.
• Over the last five years, Income towards Parent Company for EPRX reached as high as $9.4 million in Q2 2023 and fell as low as -$12.7 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$3.0 million across 4 years, with a median of -$6.0 million in 2024.
• On a YoY basis, Income towards Parent Company climbed as much as 7.03% in 2025 and fell as far as 245.51% in 2025.
• Year by year, Income towards Parent Company stood at $4.7 million in 2023, then plunged by 225.88% to -$5.9 million in 2024, then decreased by 7.03% to -$6.4 million in 2025, then plunged by 98.91% to -$12.7 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$12.7 million in Q1 2026, -$6.4 million in Q3 2025, and -$8.7 million in Q2 2025.